SUPERNUS PHARMACEUTICALS, INC. - 10-Q Filing

Supernus Pharmaceuticals reports Q3 2026 financial results including revenue from product sales and collaboration agreements.

SEC EDGAR ·

Tickers: $SUPN

Read the full article at SEC EDGAR

More Regulatory news